Moleculin Biotech (NASDAQ:MBRX) issued its quarterly earnings results on Monday. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.05), Fidelity Earnings reports.

Shares of MBRX stock traded up $0.01 on Wednesday, hitting $1.22. 785,948 shares of the stock traded hands, compared to its average volume of 2,600,803. The company has a market capitalization of $41.95 million, a price-to-earnings ratio of -2.39 and a beta of 2.26. Moleculin Biotech has a 52 week low of $0.78 and a 52 week high of $3.15.

Several research analysts have recently weighed in on MBRX shares. Zacks Investment Research cut shares of Moleculin Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 14th. Maxim Group reiterated a “buy” rating and set a $3.00 price target on shares of Moleculin Biotech in a research note on Tuesday, February 5th. Finally, ValuEngine cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, January 30th.

COPYRIGHT VIOLATION NOTICE: “Moleculin Biotech (MBRX) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/moleculin-biotech-mbrx-issues-quarterly-earnings-results-misses-expectations-by-0-05-eps/3011501.html.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.

Featured Story: Benefits of owning preferred stock

Earnings History for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.